今年 ADA 2025 大会前夕,礼来的一则 “882-P- Eloralintide一种用于肥胖的选择性长效胰淀素受体激动剂I期概念验证 / 882-P - Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity Phase 1 Proof of Concept” 壁报(将于6月22日12:30~13:...
Source Link今年 ADA 2025 大会前夕,礼来的一则 “882-P- Eloralintide一种用于肥胖的选择性长效胰淀素受体激动剂I期概念验证 / 882-P - Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity Phase 1 Proof of Concept” 壁报(将于6月22日12:30~13:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.